(Total Views: 260)
Posted On: 03/29/2021 4:33:09 AM
Post# of 653
$RLFTF DD by Clyde on Ya-h00: For recent arrivals, here are a few takeaways:
1 Relief in Switzerland has the patent for Aviptadil (VIP).
2 GEM is the main shareholder of Relief and has financed R&D.
3 NeuroRx orchestrates this project through FDA approvals.
4 Relief takes 50 % and NeuroRx 50 in North America and Israel while Relief takes 85 and NeuroRx 15 in the rest of the world. ***
5 NeuroRx's merger underway with BRPA, for eventual enlisting on NASDAQ as NRXP.
6 Relief took over German adVita for inhaler formulation of Aviptadil in return for EURO 25 mil of RLFTF common shares.
7 Relief signed an agreement with ACER, possibly for eventual enlisting on NASDAQ. 8 Bachem produces VIP (Vasoactive Intestinal Peptide). 9 TFFP now working on dry powder for inhaler feasibility.
*** #Themath $RLFTF Profits from sales will be allocated to Relief and NeuroRx on a 50/50 basis in the U.S., Canada and Israel , 85/15 (in favor of Relief) in Europe , and 80/20 (in favor of Relief) in all other territories
1 Relief in Switzerland has the patent for Aviptadil (VIP).
2 GEM is the main shareholder of Relief and has financed R&D.
3 NeuroRx orchestrates this project through FDA approvals.
4 Relief takes 50 % and NeuroRx 50 in North America and Israel while Relief takes 85 and NeuroRx 15 in the rest of the world. ***
5 NeuroRx's merger underway with BRPA, for eventual enlisting on NASDAQ as NRXP.
6 Relief took over German adVita for inhaler formulation of Aviptadil in return for EURO 25 mil of RLFTF common shares.
7 Relief signed an agreement with ACER, possibly for eventual enlisting on NASDAQ. 8 Bachem produces VIP (Vasoactive Intestinal Peptide). 9 TFFP now working on dry powder for inhaler feasibility.
*** #Themath $RLFTF Profits from sales will be allocated to Relief and NeuroRx on a 50/50 basis in the U.S., Canada and Israel , 85/15 (in favor of Relief) in Europe , and 80/20 (in favor of Relief) in all other territories
(0)
(0)
$MJ
